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Abstract 
Aim: To document the frequency of Dual-energy X-
ray absorptiometry (DEXA) scanning and Rheumatology 
clinic follow-up visits of patients with primary 
osteoporosis, and compare these with recommended 
guidelines. 
Method: Medical notes of all primary osteoporotic 
patients attending a hospital Rheumatology clinic were 
reviewed over a period of four months. Data was collected 
on age, gender, frequency of follow up visits, frequency of 
DEXA scanning, osteoporosis treatment, any changes in 
such treatment during the last visit, and comparison of the 
last two DEXA scan results.  Frequency of follow up 
DEXA scans was compared to Group Health Osteoporosis 
Screening Diagnosis and Treatment guidelines.1 
Results: Eighty-two patients were included, 6 males 
(7.3%) and 76 females (92.7%). The age range was 35-87 
years (mean age was 68.6 years).  
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In total, 42.7% of all the patients were on combined 
calcium and vitamin D, with added Bisphosphonates, 
Strontium ranelate, or Denosumab. During their last clinic 
visit, 61% showed improvement in T score since their 
previous result, and 64.6% of patients had no change in 
treatment. In this audit, 29.3% were being followed up on 
a 13 monthly basis, and 72% had annual bone mineral 
density scans or more frequently 
Conclusion: According to the guidelines, none of the 
patients included in this audit should have had a repeat 
DEXA scan within less than two years. Patients attending 
the clinic have too frequent DEXA scans and therefore, 
too frequent follow up appointments. 
 
Introduction 
Rheumatology clinics are busy and time-consuming 
for patients, doctors and nurses alike. This results in 
substantial healthcare costs as well as hidden costs for 
patients and their relatives in travelling and time taken off 
work to attend the clinic appointments. The importance is 
placed on the need to identify ways to improve efficiency 
of the clinics and minimise visits to a frequency which 
best satisfies the needs of the patient. 
A substantial number of patients attending these 
clinics are being followed up for osteoporosis. Table 1 is 
from the Group Health Osteoporosis Screening Diagnosis 
and Treatment guidelines1 for follow-up and monitoring 
of patients who have low bone mineral density (BMD) but 
who have not sustained a fracture, and who are not at high 
risk of osteoporosis due to medications or chronic 
conditions.  
According to these guidelines, most patients do not 
require Dual-energy X-ray absorptiometry (DEXA) scans 
more frequently than every two years, especially since 
osteoporosis medications take about two years to be 
effective. In addition, DEXA scanning can give errors in 
measurement.  Degenerative disease, which is common in 
elderly patients can be responsible for artefactual 
measurements, especially in the spine.  As a result, a 
minimum of 3 to 4% improvement in BMD is required to 
be able to identify any benefits from therapy, as such 
change in BMD is more likely to exceed errors in 
measurement.   Moreover, some studies have shown that 
if during the first year of treatment there is some loss in 
BMD, and the medication the patient is on remains 
unchanged, BMD may be gained in the second year of 
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treatment. This means that even if there is some loss of 
BMD during the initial period of treatment, medications 
should not be changed on the basis of such 
results.  Therefore, there is no point in repeating a DEXA 
scan before two years2.  
 
Aim 
The aim of this audit was to document the frequency 
of DEXA scanning and Rheumatology clinic follow-up 
visits of patients with primary osteoporosis, and compare 
these with recommended guidelines, in order to identify 
ways in which to improve efficiency of Rheumatology 
clinics. 
 
Method 
Consent was obtained from the Mater Dei Hospital’s 
Data Protection Officer to access the medical notes of all 
primary osteoporotic patients attending a hospital 
rheumatology clinic of one of the rheumatology 
consultants. The medical notes were reviewed and patients 
with predisposing factors for secondary osteoporosis, 
including patients on long term steroid treatment, were 
excluded, as were patients with osteopenia.  
Over a period of four months, data was collected on 
age, gender, frequency of follow up visits, frequency of 
DEXA scanning, osteoporosis treatment at last visit, any 
changes in such treatment during the last visit, and 
comparison of the last two DEXA scan results. In this 
audit, any improvement in T score, even slight, and in 
either hip or spine, was classified as an improvement in T 
score, and any deterioration in T score or same T score 
when comparing the last two DEXA scans was classified 
as no improvement in T score. 
Data was collected and analysed using Microsoft 
Excel®. 
Frequency of follow up DEXA scans was compared 
to Group Health Osteoporosis Screening Diagnosis and 
Treatment guidelines.1 
 
Results 
A total of 82 patients were included in this audit, and 
one patient had passed away in the period between the last 
clinic visit and the data collection period. There were 6 
males (7.3%) and 76 females (92.7%). The age range was 
35-87 years (average age excluding the patient who had 
passed away was 68.6 years; median age: 73 years, mode: 
73 years).  
History of a fracture was documented in the notes in 
15 patients (18.3%), however it was not always clarified 
whether this was a fragility fracture or secondary to 
trauma. 
Treatment 
There were 35 patients (42.7%) on combined calcium 
and vitamin D supplements with added Bisphosphonates, 
Strontium ranelate, or Denosumab. Nine of these 35 
patients (25.7%) were not compliant to the 
Bisphosphonates, Strontium ranelate, or Denosumab. On 
the other hand, 28.1% of patients were on calcium and 
vitamin D supplements only, and 15.9% were on 
Bisphosphonates, Strontium ranelate or Denosumab only. 
The remaining 2.4% of patients were on no treatment 
(Table 2 and Figure 1). 
Changes in Treatment during the last clinic visit 
In this audit, 48 patients (58.5%) had no change in 
osteoporosis treatment during their last clinic visit. Of 
these, 10 had a DEXA scan done at 24 months or less 
frequently, while 38 (79.1%) had had a repeat DEXA scan 
within less than 24 months. Twenty-seven of these 38 
patients (71.0%) showed improvement in their T-score, 
while the remaining 11 patients (28.9%) showed no 
improvement in T-score and yet there was no treatment 
change during their last visit when reviewed with the 
DEXA scan result. Therefore, 38 patients had a DEXA 
scan done too early, and irrespective of whether there was 
deterioration in the T score or not, there was no change in 
treatment during the last visit.  
There were 18 patients (22.0%) who had a change in 
their osteoporosis treatment, and of these, 11 (61.1%) 
showed no improvement in T score, which may have 
triggered the treatment change. In the remaining 7 patients 
(38.9%) who had shown improvement in T score, the 
reason for the osteoporosis treatment change was not 
identified. This could have been related to patients’ 
preferences or side-effects which were not documented. 
In a further 6.1%, osteoporosis treatment was documented 
to have been changed due to side-effects to the 
medication. In 60.0% of patients, no change in any 
medical treatment, including treatment for osteoporosis or 
for unrelated conditions, was made during their last 
follow-up visit. In 4.9%, compliance with osteoporosis 
medication was advised and documented in the medical 
notes. In 3.7% of patients, treatment change was advised 
but the patient decided not to go for the new treatment 
because of cost burden (Table 3 and Figure 2).  
Improvement when comparing last two DEXA scan results 
During the last visit, 61% of patients showed 
improvement in T score from the previous DEXA scan 
result documented in the medical notes. On the other 
hand, 30 patients (36.6%) did not show an improvement 
in T score, and in 2.4% it was not possible to make a 
comparison between the last two DEXA scan results 
because the results were both unavailable in the notes 
(Table 4 and Figure 3). Of the 30 patients with no 
improvement in T score, 17 (56.7%) received advice and 
had their osteoporosis treatment changed or adjusted 
during their last clinic visit. The other 13 patients (43.3%) 
showed no improvement in T score, however did not 
receive any treatment change and advice was not 
documented to have been given. 
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2
23
13
35
9
None Calcium and Vit D only Bisphos/Strontium/Denosumab Combined Calcium and Vit D,
with
Bisphos/Strontium/Denosumab
Prescribed combined Calcium
and Vit D, with
Bisphos/Strontium/Denosumab
but patient not compliant
Osteoporosis treatment at last clinic visit
Number of patients
Treatment: 
 
Table 2: shows the osteoporosis treatment that patients were on during their last visit to the hospital Rheumatology clinic. 
Bisphos = Bisphosphonates; Strontium = Strontium ranelate 
 
Current treatment Number of patients Percentage 
None 2 2.4 
Calcium and Vitamin D 
supplements only 
23 28.1 
Bisphos/Strontium/Denosumab 13 15.9 
Combined Calcium and 
Vitamin D, with 
Bisphos/Strontium/Denosumab 
35 42.7 
Prescribed combined Calcium 
and Vitamin D, with 
Bisphos/Strontium/Denosumab 
but patient not compliant to 
treatment 
9 11.0 
 
 
 
Figure 1: shows the osteoporosis treatment that patients were on during their last visit to the hospital Rheumatology clinic. 
Vit D = Vitamin D; Bisphos = Bisphosphonate ; Strontium = Strontium ranelate 
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18
49
4 3 5 3
Osteoporosis
Treatment
change
No change No osteoporosis
treatment
change but
compliance with
medication
advised
Treatment
change
considered but
patient could
not afford to buy
the new
medication
Treatment
change due to SE
Treatment
change
unrelated to
osteoporosis
medication eg
thyroxine dose
increase
Treatment change during last visit
Number of patients
Changes in Treatment during the last clinic visit: 
Table 3: shows the number and percentage of patients with changes in osteoporosis treatment made during the last 
rheumatology clinic follow up visit. 
 
 
 
 
 
 
 
 
 
 
Figure 2: shows the number of patients with changes in osteoporosis treatment made during the last rheumatology clinic 
follow up visit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Changes in Treatment Number of patients Percentage of patients 
Osteoporosis treatment 
change 
18 22.0 
No change in any treatment 49 60.0 
No osteoporosis treatment 
change, but compliance with 
medication advised 
4 4.9 
Treatment change considered 
but patients refused in view 
of cost burden 
3 3.7 
Osteoporosis treatment was 
changed due to medication 
side effects 
5 6.1 
Treatment change during last 
clinic visit was unrelated to 
osteoporosis medication 
3 3.7 
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50
30
2
Yes No Unable to make comparison as
only 1 DEXA result in file
Improvement in T score between the last 2 
DEXA results
Number of patients
Improvement when comparing last two DEXA scan results: 
Table 4: shows the improvement in T score when comparing the last 2 DEXA scan results 
Improvement in T score Number of patients Percentage 
Yes 50 61.0 
No 30 36.6 
Unable to make comparison as 
only 1 DEXA result in file 
2 2.4 
 
 
Figure 3: shows the improvement in T score when comparing the last 2 DEXA scan results 
 
 
 
 
 
 
 
 
 
 
 
 
There are two bone densitometers at Mater Dei 
hospital, but the machine used for patients’ bone density 
scan was not specified in the medical notes. 
Compliance 
There were 9 patients who were on combined 
calcium and vitamin D supplements with added 
Bisphosphonates, Strontium ranelate, or Denosumab, and 
documented to be non-compliant with treatment. Of these, 
6 (66.7%) showed no improvement in T score, and all of 
these had clinic visits scheduled more frequently than 24 
monthly, and there were 4 (44.4%) who had repeat DEXA 
scan more frequently than 24 monthly. 
Frequency of follow up visits 
Follow up visits to the clinic were 13 monthly in 
29.3% of patients, while 52.5% were being followed up 
every 12 months or more frequently (follow-up visit after 
12 months - 24.4%, 11 months – 15.9%, 10 months –  
 
 
 
 
 
3.7%, 8 months - 1.2%, 7 months - 2.4, 6 months - 
3.7%, 2 months - 1.2%). 1 patient (1.2%) was followed up 
after 1 month because of a deranged blood result unrelated 
to osteoporosis. Eleven percent of patients were followed 
up after 14 months, and 1.2% of patients were followed up  
after 15, 18, 19, 23 and 24 months each (Table 5 and 
Figure 4). 
Frequency of DEXA scans 
DEXA scan was repeated after 12 months in 65.9% 
of patients, while 6.1% of patients had more frequent 
DEXA scans (4.9% 11 months, and 1.2% 10 months). In 
this audit, 1.2% had a repeat DEXA scan after 13, 15, 18 
and 36 months each, while 15.9% had a repeat DEXA 
scan after 2 years. In 7.3% of patients it was not possible 
to determine the frequency of DEXA scans because there 
was only a single DEXA scan result available in the notes 
(Table 6 and Figure 5).  
 
 
  
 
 
 
Original Article   
 
 
 
Malta Medical Journal    Volume 25 Issue 04 2013                                                                      63                                          
 
 
1.2 1.2
3.7
2.4
1.2
3.7
15.9
24.4
29.3
11
1.2 1.2 1.2 1.2 1.2
1 2 6 7 8 10 11 12 13 14 15 18 19 23 24
Frequency of follow up visits
Percentage of patients
Frequency of follow up visits in number of months
 
Frequency of follow up visits: 
Table 5: shows the number and percentage of patients and their frequency of follow up visits in months. NB: the patient 
followed up after 1 month was given such an early follow up appointment because of deranged results not related to 
osteoporosis. 
Frequency of follow up 
visits in number of months 
Number of patients Percentage 
1 1 1.2 
2 1 1.2 
6 3 3.7 
7 2 2.4 
8 1 1.2 
10 3 3.7 
11 13 15.9 
12 20 24.4 
13 24 29.3 
14 9 11.0 
15 1 1.2 
18 1 1.2 
19 1 1.2 
23 1 1.2 
24 1 1.2 
 
 
Figure 4: shows the percentage of patients and their frequency of follow up visits in months 
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1.2%
4.9%
65.9%
1.2% 1.2% 1.2%
15.9%
1.2%
7.3%
10 11 12 13 15 18 24 36 Unknown
Number of months
Frequency of DEXA scans
percentage of patients
 
Frequency of DEXA scans: 
Table 6: shows the number and percentage of patients and the period of time between their last 2 DEXA scans. In 6 cases, 
there was only one available DEXA scan result in the notes, and so it was not possible to determine the frequency of DEXA 
scans. 
Number of months Number of patients Percentage 
10 1 1.2 
11 4 4.9 
12 54 65.9 
13 1 1.2 
15 1 1.2 
18 1 1.2 
24 13 15.9 
 36  1 1.2 
Unknown 6 7.3 
 
Figure 5: shows the percentage of patients and their frequency of DEXA scans (number of months between the last two 
DEXA scans. 
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The relationship between frequency of outpatient visits 
and frequency of DEXA scanning  
It was noted that in 16 patients (19.5%) there was a 
discrepancy between the DEXA scan frequency and the 
frequency of their follow-up appointments. Six of these 
patients (37.5%) had missed their DEXA scan 
appointment, or had not brought the DEXA scan result to 
the clinic visit. Seven patients (43.8%) were seen earlier 
then the next scheduled DEXA scan because of medical  
reasons, unrelated to osteoporosis. No reason for an earlier 
clinic visit was identified in two patients (12.5%). One 
patient (6.25%) had brought two past DEXA scan results, 
which were two years apart, to a new case appointment at 
the clinic. This same patient was then given a one-yearly 
follow-up appointment.  
 
Discussion and Conclusions 
The majority of patients suffering from primary 
osteoporosis are female, with a mean age of 68.6 years.  
As documented in the last follow up visit, most patients 
(42.7%) being followed up were on combined calcium 
and vitamin D supplements together with a 
bisphosphonate, Strontium ranelate or Denosumab. When 
keeping in mind that the patients included in this audit 
were all being followed up at a hospital Rheumatology 
clinic, this raises the question of whether the rest (57.3%) 
of the patients, the majority of which were not even on 
bone anti-resorptive treatment, may be followed up by 
their GP and referred only if complications arise. This is 
further emphasised by the fact that only in 21.9% of 
patients was there a change in osteoporosis treatment 
during their last follow up visit. For the 6.1% in whom 
osteoporosis treatment was changed due to side-effects to 
the osteoporosis medication, waiting for the next follow-
up clinic visit is unnecessary since a help-line is available 
to address such issues. 
It is reassuring that in the majority of patients 
(61.0%), an improvement in DEXA was noted during the 
last visit, when compared with the previous visit’s result. 
However, for the purpose of this audit, any amelioration 
in T score, however slight, was documented as 
improvement. This means that where there was 
deterioration in T score of the spine, but a larger 
improvement in T score of the hip, and vice versa, this 
patient was classified as having an overall improved 
BMD. Unfortunately, in view of poor documentation in 
the patients’ notes and also the lack of official DEXA scan 
results available in the notes or on the hospital online 
system, where T score “hip” was documented, it was 
impossible to tell if this referred to the T score of the neck 
of femur or the total T score. It was also not possible to 
tell whether the same bone densitometer was used when 
comparing DEXA scan results, so it was not possible to 
exclude patients who had had different bone 
densitometers used. As a result, comparison of DEXA 
scan results may have led to inaccurate data.  
Of the 30 patients with no improvement in T-score, 
17 (56.7%) received advice and had their osteoporosis 
treatment changed or adjusted during their last clinic visit. 
The other 13 patients (43.3%) did not receive any 
treatment change and advice was not documented to have 
been given. This raises the question of whether this clinic 
visit could have been avoided.  
According to Osteoporosis Screening, Diagnosis and 
Treatment Guideline by Group Health, patients who have 
never sustained a fracture, with a T score of -2.5 or less 
and taking no treatment, DEXA scans should be done 
every 2 years or less frequently (Table 1). For patients 
who are taking Bisphosphonates, DEXA scans can be 
repeated every 5 years. For patients who have sustained 
fractures, DEXA scans should be done 2-3 years after 
starting treatment. This is because medications are 
effective only 2 years after they have been started, and 
therefore fractures occurring during the first two years of 
treatment are unlikely to represent treatment failure.1 
Given the fact that according to the guidelines, none of the 
patients included in this audit should have had a repeat 
DEXA scan within less than two years, it is important to 
note that 72% of patients whose notes were reviewed had 
12 monthly DEXA scans or more. The patients then had a 
follow up appointment at the clinic to review the result 
and this led to increased unnecessary visits to the clinic, 
with most patients having an eleven to fourteen monthly 
follow up visit. This is further emphasised by the fact that 
most patients (64.6%) had no change in osteoporosis 
treatment during their last visit at the clinic.  
A review of published research on strategies and 
processes involving primary care that influence the 
efficiency and effectiveness of outpatient services showed 
that discharging patients to primary care follow up results 
in improved access and reduced outpatient attendance, 
without adverse effects on the quality of care. This leads 
to overall reduced NHS costs, despite increased primary 
care workload. This however would require primary care 
physicians to be able to request and have access to the 
results of hospital based investigations.4 
 
Limitations 
Fractures had been documented in the patient notes in 
18.3%, but it was not specified whether these were 
fragility fractures or not.  Nonetheless, in many patients 
there was no documentation of whether the patient had 
had any past history of fractures or not.  
There are two bone densitometers at Mater Dei hospital. 
Before any change in T-score is analysed and acted upon, 
it should be ascertained that the same bone densitometer is 
used for the patient’s bone mineral density scan. In this 
audit it was not possible to assess whether this is being 
done during the clinic because the machine used for 
patients’ bone density scan was not specified in the medical notes. 
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This audit highlights poor documentation of DEXA 
scan results and raises the concern that DEXA scan results 
are not available on the hospital online results system, 
meaning that results are often lost, or kept by the patient 
without a copy in the file, making quick access to results 
impossible. 
 
Suggestions 
DEXA scan results should be uploaded with the 
rest of radiological studies on PACs, making them readily 
available for all doctors caring for the patient, who need to 
access them and compare to previous results. 
Table 1: Group Health Osteoporosis Screening Diagnosis and Treatment guidelines1 for follow-up and monitoring of 
patients who have low bone density. 
DEXA = Dual-energy X-ray absorptiometry scan 
Baseline or most recent DEXA T score 
and/or clinical circumstances 
 
Recommended screening interval 
Higher than -1.5  
 
Repeat DEXA scan only if the number of risk 
factors increases or there is a clinical concern 
regarding osteoporosis 
-1.5 to -1.9  May choose to repeat DEXA scan in 5 years 
-2.0 to -2.4  May choose to repeat DEXA in 2 years 
-2.5 or lower, choosing no treatment  
 
Repeat DEXA scan as clinically indicated but 
no more frequently than every 2 years 
-2.5 or lower, choosing  
bisphosphonates  
May choose to repeat DEXA scan in 5 years 
Patients on chronic steroids  
 
Repeat the DEXA scan 6 months after the 
initiation of corticosteroid treatment and 
annually thereafter (expert opinion) 
Patients at high risk due to comorbid  
conditions, and patients with fractures  
Repeat DEXA scan after 2–3 years of 
treatment 
 
 
Burden on the rheumatology clinics can be lessened 
significantly if stable, mild, and uncomplicated cases of 
primary osteoporosis are followed up by their GP, and 
referred only if any deterioration or complications arise. 
This may be achieved by means of referral guidelines for 
primary care physicians. The load on the clinics can be 
further reduced, together with the patients’ radiation-
exposure, by following the latest guidelines on frequency 
of DEXA scanning and follow-up.  
The World Health Organisation (WHO) fracture risk 
assessment (FRAX) score was not documented in the 
medical notes of any of the patients seen for osteoporosis. 
The FRAX tool is used to identify the ten year probability 
of fracture, and the aim of osteoporotic treatment is 
ultimately to reduce this risk. The setting up of specific 
osteoporosis clinics may allow more time and attention to 
be dedicated to calculating and documenting the FRAX 
score at every visit. This could be more beneficial as a 
guide to patient improvement or deterioration than the T 
score in isolation.   
 
 
 
 
Unfortunately, it is not known whether using either 
FRAX or QFracture risk assessment tools can reliably 
estimate the risk of fractures in treated osteoporotic 
patients as in untreated patients.  Further studies are 
required with regards to this issue5.     
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